These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38262639)

  • 21. Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions.
    Durant AM; Choudry MM; Madura G; Mi L; Faraj KS; Tyson MD
    Urol Oncol; 2024 Jan; 42(1):21.e21-21.e28. PubMed ID: 37852817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
    Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
    Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes.
    Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi PF
    BMC Cancer; 2018 Dec; 18(1):1224. PubMed ID: 30522445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective descriptive 1-year study in France of all BCG therapy dispensations for non-muscle-invasive bladder cancer.
    Neuzillet Y; Leon P; Seisen T; Allory Y; Audenet F; Loriot Y; Masson-Lecomte A; Mejean A; Pradère B; Roumiguié M; Traxer O; Xylinas E; Fournier G; Roupret M
    BJU Int; 2023 May; 131(5):611-616. PubMed ID: 36462164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial DUrvalumab injection-1 study): clinical trial protocol.
    Moe A; Liow E; Redfern A; Swarbrick N; Ferguson T; Davis ID; Hayne D
    BJU Int; 2021 Oct; 128 Suppl 1():9-17. PubMed ID: 33960102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer.
    Packiam VT; Richards J; Schmautz M; Heidenreich A; Boorjian SA
    Curr Opin Urol; 2021 May; 31(3):178-187. PubMed ID: 33742981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?
    Sari Motlagh R; Pradere B; Mori K; Miura N; Abufaraj M; Shariat SF
    Curr Opin Urol; 2020 Jul; 30(4):584-593. PubMed ID: 32304379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer.
    Al Hussein Al Awamlh B; Chang SS
    Curr Oncol Rep; 2023 Feb; 25(2):83-91. PubMed ID: 36571706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC.
    Kamat AM; Shore N; Hahn N; Alanee S; Nishiyama H; Shariat S; Nam K; Kapadia E; Frenkl T; Steinberg G
    Future Oncol; 2020 Apr; 16(10):507-516. PubMed ID: 32162533
    [No Abstract]   [Full Text] [Related]  

  • 31. BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets.
    Claps F; Pavan N; Ongaro L; Tierno D; Grassi G; Trombetta C; Tulone G; Simonato A; Bartoletti R; Mertens LS; van Rhijn BWG; Mir MC; Scaggiante B
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protocol for hypofractionated adaptive radiotherapy to the bladder within a multicentre phase II randomised trial: radiotherapy planning and delivery guidance.
    Hafeez S; Patel E; Webster A; Warren-Oseni K; Hansen V; McNair H; Miles E; Lewis R; Hall E; Huddart R
    BMJ Open; 2020 May; 10(5):e037134. PubMed ID: 32461298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy.
    Yim K; Melnick K; Mott SL; Carvalho FLF; Zafar A; Clinton TN; Mossanen M; Steele GS; Hirsch M; Rizzo N; Wu CL; Mouw KW; Wszolek M; Salari K; Feldman A; Kibel AS; O'Donnell MA; Preston MA
    Urol Oncol; 2023 Nov; 41(11):458.e1-458.e7. PubMed ID: 37690933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
    Steinberg GD; Shore ND; Redorta JP; Galsky MD; Bedke J; Ku JH; Kretkowski M; Hu H; Penkov K; Vermette JJ; Tarazi JC; Randall AE; Pierce KJ; Saltzstein D; Powles TB
    Future Oncol; 2024 May; 20(14):891-901. PubMed ID: 38189180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: a study protocol for an open-label, two-cohort, phase II trial.
    Yuk HD; Jeong CW; Kwak C; Kim H; Moon KC; Ku JH
    BMJ Open; 2020 Oct; 10(10):e035530. PubMed ID: 33060077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis.
    Kamat AM; Lerner SP; O'Donnell M; Georgieva MV; Yang M; Inman BA; Kassouf W; Boorjian SA; Tyson MD; Kulkarni GS; Chang SS; Konety BR; Svatek RS; Balar A; Witjes JA
    Eur Urol Oncol; 2020 Jun; 3(3):318-340. PubMed ID: 32201133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
    Boorjian SA; Alemozaffar M; Konety BR; Shore ND; Gomella LG; Kamat AM; Bivalacqua TJ; Montgomery JS; Lerner SP; Busby JE; Poch M; Crispen PL; Steinberg GD; Schuckman AK; Downs TM; Svatek RS; Mashni J; Lane BR; Guzzo TJ; Bratslavsky G; Karsh LI; Woods ME; Brown G; Canter D; Luchey A; Lotan Y; Krupski T; Inman BA; Williams MB; Cookson MS; Keegan KA; Andriole GL; Sankin AI; Boyd A; O'Donnell MA; Sawutz D; Philipson R; Coll R; Narayan VM; Treasure FP; Yla-Herttuala S; Parker NR; Dinney CPN
    Lancet Oncol; 2021 Jan; 22(1):107-117. PubMed ID: 33253641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
    Miyake M; Nishimura N; Fujii T; Fujimoto K
    Int J Urol; 2023 Nov; 30(11):944-957. PubMed ID: 37522629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.